Back
Full-text
Journal article

International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.

  • Crunelle CL Department of Psychiatry, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • van den Brink W Amsterdam Institute of Addiction Research (AIAR), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Moggi F University Hospital of Psychiatry, University of Bern, Bern, Switzerland.
  • Konstenius M Karolinska Institutet, Stockholm, Sweden.
  • Franck J Karolinska Institutet, Stockholm, Sweden.
  • Levin FR Columbia University, New York State Psychiatric Institute, New York, New York, USA.
  • van de Glind G ICASA Foundation, University of Amsterdam, Amsterdam, the Netherlands.
  • Demetrovics Z Eötvös Loránd University, Budapest, Hungary.
  • Coetzee C Department of Pharmacy, University of Limpopo, Sovenga, South Africa.
  • Luderer M Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.
  • Schellekens A Department of Psychiatry, Radboudumc, Donders Institute for Brain, Cognition and Behavior, Nijmegen Institute for Scientist Practitioners in Addiction (NISPA), Nijmegen, the Netherlands.
  • Matthys F
Show more…
  • 2018-03-07
Published in:
  • European addiction research. - 2018
Attention deficit/hyperactivity disorder
Consensus
Diagnosis
Substance use disorders
Treatment
Adult
Attention Deficit Disorder with Hyperactivity
Central Nervous System Stimulants
Comorbidity
Consensus
Humans
Internationality
Mass Screening
Methylphenidate
Psychotherapy
Risk Factors
Substance-Related Disorders
Treatment Outcome
English Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.
Language
  • English
Open access status
green
Identifiers
Persistent URL
https://sonar.rero.ch/global/documents/44329
Statistics
Document views: 46 File downloads:
  • Full-text: 0